Cancer Genetics gets Nasdaq noncompliance notice
Essential IR Insights Newsletter Fall - 2023
A Corporation Clearly Pinpoints Activist Investor Activity
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Rutherford, N.J.-based Cancer Genetics Inc. said it failed to comply with Nasdaq's $1 minimum bid price per share for its common shares.
The biotechnology company, which develops molecular and biomarker-based tests and services, has 180 calendar days, or until Feb. 4, 2019, to regain compliance.
